Alphamab Oncology
Alphamab Oncology Waste Data Preview
In 2023, Alphamab Oncology conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
Insights into Alphamab Oncology’s Generation of Hazardous and Non-Hazardous Waste
In 2023, Alphamab Oncology generated a total of 274 metric tonnes of waste.
Of this amount, 98.9% of Alphamab Oncology's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 1.1% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Alphamab Oncology’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How Alphamab Oncology reduced the environmental impact of its waste?
Since 2021, Alphamab Oncology's total waste generation increased by 203.08%, including a 24.05% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, the share of hazardous waste in Alphamab Oncology's total output increased by 20.86%, including a further 1.15% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.
Overall, while Alphamab Oncology has recently reduced waste output, its hazardous waste share continues to rise, raising concerns about treatment efficiency or growing reliance on harmful materials despite short-term volume improvements.